Chemical Structure (Xeljanz 01)
Xeljanz Tablet, Film Coated
Product Images NDC 63539-012
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Xeljanz (NDC 63539-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Xeljanz 02)
This appears to be a table of recommendations for dose adjustment based on various factors such as age, weight, ethnicity, and severity of renal or hepatic impairment. The table provides a ratio relative to a reference and a recommendation for dose adjustment or no adjustment.*
Figure 2 (Xeljanz 03)
This text provides drug dosage recommendations for Methotrexate, Midazolam, Oral Contraceptives, Levonorgestrel, Ethinyl estradiol, and Metformin. These recommendations include adjustments for drug exposure (AUC) and concentration (Cmax), and whether the drug is a CYP3A substrate or OCT & MATE substrate. The text also includes a chart illustrating the ratio relative to reference for each drug.*
Figure 3 (Xeljanz 04)
Figure 4 (Xeljanz 05)
Figure 5 (Xeljanz 06)
This is a chart that displays response rates for XELIANZS and placebo over the course of 3 months. The chart also indicates that non-responder imputation was used in the study.*
Figure 6 (Xeljanz 07)
Logo (Xeljanz 08)
This appears to be a table or graph displaying the results of a clinical trial comparing the use of tofacitinib 5 mg BID to a placebo. The table shows the number of participants in each group (N=88 for tofacitinib, N=85 for placebo) and the occurrence of something over a period of several weeks (possibly a side effect or symptom). However, the actual occurrence and what is being measured is not provided, so a more specific description is not available.*
Principal Display Panel (5 mg Tablet Bottle Label)
This is a brief text containing information regarding the distribution of a product by Pfizer Labs - a division of Pfizer Inc. The location mentioned is at NY, NY 10017.*
Principal Display Panel (11 mg Tablet Bottle Label)
This text seems to be a label of a product which says the product is distributed by Pfizer Labs, which is a division of Pfizer Inc located in NY, NY 10017. It doesn't provide any information about what the product is.*
Principal Display Panel (10 mg Tablet Bottle Label)
This text describes a package of medication called XELJANZ oral solution, which includes a press-in bottle adapter and an oral dosing syringe. The adapter and syringe are used to measure the appropriate amount of medication for oral consumption. The text includes details on the design of the adapter and syringe, as well as the packaging of the medication, but does not provide information on the dosage or instructions for use.*
Principal Display Panel (22 mg Tablet Bottle Label)
Xeljanz 14
Xeljanz 15
Xeljanz 16
Xeljanz 17
Xeljanz 18
Xeljanz 19
Xeljanz 20
Xeljanz 21
Xeljanz 22
Xeljanz 23
Xeljanz 24
This text indicates that the mentioned product is distributed by Pfizer Labs, which is a division of Pfizer Inc located in NY, NY 10017.*
Xeljanz 25
This is a description of the storage instructions for Xeljanz (tofacitinib tablets), a medication distributed by Pfizer Inc in the USA. It should be stored between 20°C to 25°C (68°F to 77°F), with excursions between 15°C to 30°C permitted (59°F to 86°F). It is indicated that the medication should not be repackaged, and dosage/usage instructions should be followed as per the accompanying prescribing information. The tablets contain 8 mg tofacitinib citrate, equivalent to 5 mg tofacitinib. This specific document appears to be a professional sample, not for sale, and includes the unique identifier NDC 63539-012-02 and the Lot number 413259.*
Xeljanz 26
This is a description of a medication called Xeljanz XR, containing tofacitinib citrate equivalent to 11 mg tofactin. It comes in a bottle of 30 extended-release tablets and should be stored at 20-25°C (68-77°F) in accordance with USP standards. Repackaging is prohibited and it should always be dispensed along with the medication guide. For dosage and use, the accompanying prescribing information should be consulted. It is distributed by U.S. Pharmaceuticals and made in Ireland. This text also includes the NDC and lot number PAAD66804.*
Xeljanz 27
This text is a product description for Xeljanz tablets containing tofacitinib citrate for the treatment of ulcerative colitis. It indicates the dosage and advises not to repackage. The tablets are distributed by U.S. Pharmaceuticals and contain 16mg of tofacitinib citrate, equivalent to 1010mg of tofacitinib per tablet. The tablets should be stored between 20°C and 25°C. It also shows the product's NDC code and a lot number. It is a professional sample and not for sale.*
Xeljanz 28
This is a medication called Xeljanz XR, containing tofacitinib, which comes in the form of extended-release tablets. Each tablet contains 2mg of tofacitinib. It is recommended to store the medication at a temperature between 20°C to 25°C (68°F to 77°F) and it should not be repackaged. Dosage and administration information is available in the accompanying prescribing information. The product is distributed by Pfizer Inc. and manufactured in Ireland. It is a professional sample and not for sale. The 22mg strength is only recommended for ulcerative colitis. The National Drug Code for this product is 63539-502-30, and it comes in a package of 30 tablets.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
